MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 28 2023 - 6:00AM
MannKind Corporation (Nasdaq: MNKD) a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will present at the 42nd Annual J.P. Morgan
Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST
at the Westin St. Francis Hotel in San Francisco, California.
Those interested in listening to the webcast may do so by
visiting the Company's website at Investors/Events &
Presentations or
https://investors.mannkindcorp.com/events-and-presentations. The
webcast will also be archived and available for
replay.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact: Rose
Alinaya, Investor Relations(818) 661-5000Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024